Clinical Trials Browser

Head and Neck Carcinoma × pembrolizumab × Head & Neck × Clear all

NCT02718820 2024-01-09

Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

Phase 1/2 Completed

22 enrolled 10 charts

Head and Neck Carcinoma